• DOI:10.1161/ATVBAHA.114.304486
Corpus ID: 36822867

Rising like the phoenix?

@article{Plow2014RisingLT,
  title={Rising like the phoenix?},
  author={E. Plow and Mitali Das},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  year={2014},
  volume={34 10},
  pages={
          2182-3
        }
}

• E. Plow, Mitali Das
• Published 2014
• Medicine
• Arteriosclerosis, thrombosis, and vascular biology

Depending on one’s perspective, αIIbβ3 antagonists can be viewed as a great success story or as an exasperating disappointment.1 Certainly, millions of patients have been treated with the 3 Food and Drug Administration–approved αIIbβ3 antagonists, abciximab, eptifibatide, tirofiban; based on their reduction in mortality in clinical trials, one can calculate that many lives have been saved by these drugs2 and they continue to be administered to prevent thrombotic events, primarily in the setting… Expand

View on PubMed

ahajournals.org

Save to Library

Create Alert

Cite

Launch Research Feed